Authors: | Johannet, P.; Friedman, C. F. |
Review Title: | The intrauterine device: How to deploy this strategy in the molecular world? |
Abstract: | Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073. ©2024 American Association for Cancer Research. |
Keywords: | endometrial neoplasms; pathology; drug therapy; endometrium tumor; fertility preservation; gestagen; levonorgestrel; endometrial hyperplasia; endometrium hyperplasia; procedures; humans; human; female; progestins; intrauterine contraceptive device; intrauterine devices, medicated; intrauterine devices |
Journal Title: | Clinical Cancer Research |
Volume: | 30 |
Issue: | 22 |
ISSN: | 1078-0432 |
Publisher: | American Association for Cancer Research |
Date Published: | 2024-11-15 |
Start Page: | 5001 |
End Page: | 5002 |
Language: | English |
DOI: | 10.1158/1078-0432.Ccr-24-2034 |
PUBMED: | 39254401 |
PROVIDER: | scopus |
PMCID: | PMC11567785 |
DOI/URL: | |
Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Claire F. Friedman -- Source: Scopus |